Document is current
Any future updates will be listed below
-
Authors
Fulgenzi, Claudia A. M.
Dalla Pria, Alessia
Leone, Alberto Giovanni
Martinez, Maria
Del Peral, Elena Ferrer Martinez
Flores, Maria Eleanor
Bower, Mark
Pinato, David J.
- License Information
-
More Information
Article History
Received: 19 November 2024
Accepted: 13 May 2025
First Online: 1 July 2025
Declarations
:
: The study was reviewed and approved by the London South East NHS Ethics Committee, the UK Medicines and Healthcare products Regulatory Agency and the UK Health Research Authority (IRAS ID 1004389). The study is performed in compliance with the declaration of Helsinki and the principles of Good Clinical Practice. Signed informed consent is obtained from each patient before study entry.
: Not applicable.
: DJP received lecture fees from ViiV Healthcare, Bayer Healthcare, BMS, Roche, Eisai, Falk Foundation, travel expenses from BMS and Bayer Healthcare; consulting fees for Mina Therapeutics, EISAI, Roche, DaVolterra, Mursla, Exact Sciences and Astra Zeneca; research funding (to institution) from MSD, GSK and BMS. CAMF received lecture fees from EISAI and AstraZeneca.
